High response rate to darbopoetin alfa in "low risk" MDS: Results of a phase II study.

被引：0
|
作者：
Mannone, L [1 ]
Gardin, C [1 ]
Quarre, MC [1 ]
Bernard, JF [1 ]
Giraudier, S [1 ]
Rosenthal, E [1 ]
Vassilief, D [1 ]
Hamza, F [1 ]
Park, S [1 ]
Kiladjian, JJ [1 ]
Vaultier, S [1 ]
Beyne-Rouzy, M [1 ]
Cheze, S [1 ]
Voilliat, L [1 ]
Agape, P [1 ]
Dreyfus, F [1 ]
Fenaux, P [1 ]
机构：
[1] GFM, Paris 13, France
来源：
BLOOD | 2004年 / 104卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
69
引用
收藏
页码：24A / 24A
页数：1
相关论文
共 50 条
  • [41] Phase II study of gemcitabine in pretreated Hodgkin's disease results of a multicenter study.
    Tesch, H
    Santoro, A
    Fiedler, F
    Bonadonna, G
    Bredenfeld, K
    Oliva, C
    Buksmaui, S
    Sieber, M
    Diehl, V
    BLOOD, 1997, 90 (10) : 1514 - 1514
  • [42] A Phase II Study of Post-Remission Therapy with Azacitidine (AZA) in Patients with AML Post-MDS and High-Risk MDS: A GFM Group Study
    Gardin, Claude
    Prebet, Thomas
    Bouabdallah, Krimo
    Caillot, Denis
    Guerci, Agnes
    Raffoux, Emmanuel
    Marolleau, Jean Pierre
    Pautas, Cecile
    Banos, Anne
    Himberlin, Chantal
    Taksin, Anne-Laure
    Pigneux, Arnaud
    Thomas, Xavier
    Jernival, Tony
    Vey, Norbert
    Dreyfus, Francois
    Chevret, Sylvie
    Dombret, Herve
    Fenaux, Pierre
    BLOOD, 2009, 114 (22) : 348 - 348
  • [43] PBI with interstitial high-dose-rate brachytherapy: results of a phase II prospective study
    Lancellotta, V.
    Chirico, L.
    Palumbo, I.
    Anselmo, P.
    Zucchetti, C.
    Italiani, M.
    Bini, V.
    Maranzano, E.
    Aristei, C.
    RADIOTHERAPY AND ONCOLOGY, 2015, 115 : S19 - S20
  • [44] EPIGENETIC THERAPY WITH S-AZACITIDINE, VALPROIC ACID, AND ATRA IN PATIENTS WITH HIGH-RISK AML OR MDS: RESULTS OF THE FRENCH VIVEDEP PHASE II STUDY
    Raffoux, E.
    Recher, C.
    Gardin, C.
    Marolleau, J. P.
    Reman, O.
    Cras, A.
    Turlure, P.
    Maury, S.
    De Labarthe, A.
    Degos, L.
    Chevret, S.
    Chomienne, C.
    Dombret, H.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 303 - 303
  • [45] Epigenetic Therapy with 5-Azacitidine, Valproic Acid, and ATRA in Patients with High-Risk AML or MDS: Results of the French VIVEDEP Phase II Study
    Raffoux, Emmanuel
    de Labarthe, Adrienne
    Cras, Audrey
    Recher, Christian
    Turlure, Pascal
    Marolleau, Jean-Pierre
    Reman, Oumedaly
    Gardin, Claude
    Maury, Sebastien
    Rousselot, Philippe
    Malfuson, Jean-Valere
    Maarek, Odile
    Degos, Laurent
    Chomienne, Christine
    Dombret, Herve
    BLOOD, 2008, 112 (11) : 283 - 283
  • [46] THE ADDITION OF LENALIDOMIDE TO AZACITIDINE IN HIGHER RISK MDS IS DELIVERABLE WITH HIGHER RESPONSE RATES; FIRST ANALYSIS OF THE ALLG MDS4 RANDOMISED PHASE II STUDY
    Kenealy, M.
    Benson, W.
    Stevenson, W.
    Eek, R.
    Zantomio, D.
    Cunningham, I.
    Hiwase, D.
    Vlachos, S.
    Zannino, D.
    Seymour, J. F.
    HAEMATOLOGICA, 2014, 99 : 499 - 500
  • [47] Phase I/II Combination Study of Azacitidine and Venetoclax Post Hypomethylating Agents Failure in High Risk MDS and CMML
    Braish, Julie
    Montalban-Bravo, Guillermo
    Ravandi, Farhad
    Short, Nicholas J.
    Kadia, Tapan M.
    Ohanian, Maro
    Chien, Kelly S.
    Masarova, Lucia
    Sasaki, Koji
    Yilmaz, Musa
    Daver, Naval
    Borthakur, Gautam
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    BLOOD, 2024, 144 : 3209 - 3210
  • [48] Azacitidine (AZA) plus idarubicin (IDA) in untreated high-risk MDS - A GFM phase I/II study
    Ades, L.
    De Renzis, B.
    Jeddi, R.
    Delaunay, J.
    Braun, T.
    Hunault-Berger, M.
    Stamatoullas, A.
    Sanhes, L.
    Samey, B.
    Chermat, F.
    Meddeb, B.
    Fenaux, P.
    LEUKEMIA RESEARCH, 2013, 37 : S13 - S13
  • [49] A Phase I/II Study Of Cytarabine Or Azacitidine In Combination With Tosedostat In Older Patients With AML Or High-Risk MDS
    DiNardo, Courtney D.
    Kantarjian, Hagop M.
    Ravandi, Farhad
    Konopleva, Marina
    Kadia, Tapan M.
    Borthakur, Gautam
    Daver, Naval G.
    Durand, Mends
    Rivera, Silvia
    Quintas-Cardama, Alfonso
    Garcia-Manero, Guillermo
    Cortes, Jorge E.
    BLOOD, 2013, 122 (21)
  • [50] SBRT in low- and intermediate-risk prostate cancer: results of a phase II study
    D'Agostino, G.
    Villa, E.
    Franzese, C.
    Liardo, R.
    Reggiori, G.
    Navarria, P.
    Iftode, C.
    De Rose, F.
    Franceschini, D.
    Tozzi, A.
    Comito, T.
    Ascolese, A.
    Tomatis, S.
    Scorsetti, M.
    RADIOTHERAPY AND ONCOLOGY, 2016, 119 : S628 - S629
12345